| "The incidence of infections was studied in 137 iron-deficient Somali nomads, 67 of whom were treated with placebo and 71 with iron." | ( Murray, AB; Murray, CJ; Murray, MB; Murray, MJ, 1978) |
| "Nevertheless, these pre-transplantation infections should not exclude the possibility of bone marrow transplantation if they can be successfully controlled with specific antimicrobial therapy and necessary adjunctive measures." | ( Gale, RP; Meyer, DV; Winston, DJ; Young, LS, 1979) |
| "Actuarial analysis of infections after these two treatment modes showed that the treatment-related increase in infection was nearly exclusively due to the latter form of therapy." | ( Hunt, SA; Mason, JW; Rider, AK; Schroeder, JS; Stinson, EB, 1976) |
| "Most serious hand infections are preventable at this time if proper prophylaxis is maintained with regard to the hands and if the precursor conditions-mild inflammations and infections-are quickly and appropriately treated." | ( Dobyns, JH; Linscheid, RL, 1975) |
| "There were three patients with fatal infections who had no evidence of disease after they had finished treatment." | ( Beresi, V; Chamas, N; DelPozo, H; Diaz, V; Geldres, V; Henriquez, A; Latorre, JJ; Macho, L; Quintana, J; Sepulveda, L, 1991) |
| "During the first 3 months the number of infections was significantly lower in the CsA/P treatment than in the CsA/Aza/P group." | ( Thompson, J; van der Woude, FJ; van Dorp, WT; van Es, LA, 1991) |
| "The incidence of documented mycotic infections as well as the detection of fungi in surveillance cultures was similar in both treatment groups." | ( Daenen, S; de Pauw, BE; de Vries-Hospers, HG; Dekker, AW; Donnelly, JP; Gaus, W; Haralambie, E; Kern, W; Konrad, H; Maschmeyer, G, 1990) |
| "Because these infections can be very damaging to the hand or wrist, treatment should be rendered promptly and adequately." | ( Gunther, SF, 1990) |
| "Many hand infections can produce permanent disability if not treated promptly and aggressively." | ( Scheker, LR; Weeks, LE, 1990) |
| "There was one infection-related death among patients assigned to AAT therapy and also one among those assigned to LAT therapy." | ( Ichimaru, M; Moriuchi, Y; Soda, H; Tomonaga, M; Toriya, K, 1989) |
| "Fungal infections may need to be treated for as long as a year." | ( Stone, OJ, 1989) |
| "We compared the infections encountered in 23 renal transplant patients given the monoclonal anti-T-cell antibody, Orthoclone OKT3 (OKT3), for treatment of steroid-resistant rejection in 1986 and in 23 control patients from 1984 to 1985 with resistant rejection matched demographically, for severity of rejection and for risk factors predisposing to infection, who did not receive OKT3; recipients of OKT3 received substantially less prednisone, cyclosporine, and antilymphocyte globulin (ALG) than control patients for treatment of the rejection episode." | ( Belzer, FO; Fox, BC; Maki, DG; Oh, CS; Sollinger, HW; Stratta, RJ, 1988) |
| "Thirty-five patients with serious infections and impaired renal function were treated empirically with 2 to 8 g of cefoperazone per day." | ( Caputo, GM; Colao, DJ; Sattler, FR; Schoolwerth, AC, 1986) |
| "Some forms of posttransplant infection, including those associated with herpes simplex and cytomegalovirus, can now be prevented or treated." | ( Appelbaum, FR; Thomas, ED, 1985) |
| "In patients with intra-abdominal infection, those treated with MOX are more likely to develop abnormal PT than those treated with TM/C." | ( Baxter, JG; Marble, DA; Schentag, JJ; Walczak, P; Wels, PB; Whitfield, LR, 1985) |
| "At Lovelace Medical Center, infections of the musculoskeletal system have accounted for two thirds of the cases for which such therapy is used." | ( Grizzard, MB, 1985) |
| "In a more chronic bacterial infection due to Corynebacterium kutscheri, hydrocortisone produced striking deleterious effects on resistance, whereas indomethacin administration in doses approaching the maximal tolerated level caused no observable adverse effects on host resistance." | ( Graessle, OE; Phares, HF; Robinson, HJ, 1968) |
| "In many neurosurgery-associated infections, intrathecal or intraventricular antibiotics may be required to supplement parenteral treatment and/or surgical intervention." | ( Everett, ED; Strausbaugh, LJ, 1980) |
| "The risks from infection in infancy and childhood due to asplenia ae now well known, and children at risk ar being identified and treated." | ( Milner, PF, 1981) |
| "Intra-abdominal infection developed in 7 of 21 (33%) who had a persistent leukocytosis, but no intra-abdominal infections developed after operation in 30 patients who had normal WBC counts at the end of antibiotic treatment (p less than 0." | ( Dellinger, EP; Lennard, ES; Minshew, BH; Wertz, MJ, 1982) |
| "The major complication of treatment was infection and four patients died from infection following HDMP." | ( Barrett, AJ; Desai, M; Halil, O; Hobbs, JR; Hugh-Jones, K; Joshi, R; Joss, V; Kendra, J; Lucas, C; Rogers, TR, 1981) |
| "Records of 133 infections occurring in 73 of 125 patients with late-stage non-Hodgkin's lymphoma on intensive chemotherapy programs for a median of 23 months were reviewed." | ( Bishop, JF; Diggs, CH; Schimpff, SC; Wiernik, PH, 1981) |
| "At two weeks there had been two wound infections (one resolved spontaneously and the other required removal of a gallstone from the subcutaneous tissue), two chest infections (treated with antibiotics orally and physiotherapy), and one subhepatic abscess (drained percutaneously under ultrasonographic control)." | ( Leaper, DJ; Thompson, MH; Wainwright, AM; Watkin, DS, 1995) |
| "Twelve patients developed infections during treatment." | ( Niitsu, N; Umeda, M, 1995) |
| "In the treatment of serious infection by aminoglycoside antibiotics multiple daily treatment with netilmicin is considered to be the least toxic." | ( Büller, HR; Dreschler, WA; Kuijper, EJ; Prins, JM; Speelman, P; Tange, RA, 1995) |
| "rhGM-CSF reduced the incidence of infections in the first cycle of chemotherapy, but no benefit beyond the initial chemotherapy cycle was evident." | ( Bajorin, DF; Bokemeyer, C; Bosl, GJ; Demetri, GD; Einhorn, LH; Kantoff, PW; Nichols, CR; Schmoll, HJ, 1995) |
| "Improperly treated hand infections can lead to severe disability including stiffness, contracture, and amputation." | ( Brown, DM; Young, VL, 1993) |
| "Despite several infections including urinary tract infection (n = 8), peritonitis (n = 1), shunt infection (n = 1), bronchitis (n = 1), salmonellosis (n = 1), herpes stomatitis (n = 2), herpes zoster (n = 1), and cytomegalovirus (n = 1), and despite treatment of several rejection episodes (n = 8), none of them had or has infections typical of the acquired immunodeficiency syndrome (AIDS)." | ( Bennhold, I; Keller, F; Krause, PH; L'age-Stehr, J; Mihatsch, MJ; Offermann, G; Schwarz, A, 1993) |
| "105 patients with various infections were hospitalized and treated." | ( Alappan, R; Buller, GK; Perazella, MA, 1996) |
| "The major treatment-emergent AE were infection (50%, 8 of 16) and sleep disturbance (19%, 3 of 16)." | ( Donaldson, JA; Glauser, TA; Olberding, LS, 1997) |
| "The frequency of respiratory tract infections with a presumed viral etiology that were diagnosed and treated with antibiotics increased by 86% for adults and 115% for children in the 11-year period." | ( Balkau, B; Bouvenot, G; Carbon, C; Eschwège, E; Guillemot, D; Maison, P; Sermet, C; Vauzelle-Kervroëdan, F, 1998) |
| "There was no association of infections or febrile episodes with the use of corticosteroids or the CD4 count at the end of treatment and a poor correlation with the increase in CD4 counts during remission." | ( Beran, M; Estey, E; Freireich, EJ; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; O'Brien, S; Robertson, LE, 1998) |
| "These frequent infections occur despite aggressive treatment with appropriate diets, carnitine and during acute episodes of the disease with metronidazole, which suggests a global effect of the disease on T and B lymphocytes as well as on the bone marrow cells." | ( Al Amoudi, M; Al Essa, M; Al Jishi, E; Joshi, S; Jumaah, S; Ozand, PT; Rahbeeni, Z; Rashed, MS, 1998) |
| "In the treatment of severe infections complicated to blood dyscrasia, the efficacy and usefulness of fosfomycin (FOM) in combination with sulbactam (SBT)/cefoperazone (CPZ) were compared between patients receiving FOM in the first followed by SBT/CPZ (Group A) and those receiving both drugs simultaneously (Group B)." | ( Ann, E; Bessho, M; Dan, K; Egashira, M; Fukuda, M; Hirai, H; Hirasawa, A; Hirashima, K; Hoshino, T; Hosoya, N; Ikeda, Y; Karasawa, M; Kawai, N; Kitamura, K; Kizaki, M; Miura, Y; Miyazawa, K; Nagasu, M; Naruse, T; Noguchi, M; Ohmine, K; Oshimi, K; Sugai, M; Takagi, S; Toyama, K, 1998) |
| "Bacterial infections were more common in MMF-treated patients, but this cohort had a prolonged intensive care unit stay compared with patients who did not receive MMF." | ( Gayowski, T; Marino, IR; Panebianco, A; Paterson, DL; Singh, N; Wagener, MM; Wannstedt, CF, 1998) |
| "Drug therapy for deeply invasive infections with this organism has been ineffective in humans and animals; patients have been cured only by radical surgical debridement." | ( English, BK; Frisch, G; Kaufman, L; Kaufman, RA; Pearson, TA; Rinaldi, MG; Shenep, JL; Thompson, JW, 1998) |
| "Severe infections are a major problem in patients suffering from acute nonlymphocytic leukemia (ANLL) undergoing myeloablative chemotherapy." | ( Diehl, V; Engert, A; Hegener, K; Hübel, K; Mansmann, G; Oberhäuser, F; Schnell, R; Staib, P, 1999) |
| "However, severe infections should not be treated with oral chloramphenicol in this age group, because therapeutic serum concentrations were inconsistently achieved." | ( Gatchalian, SR; McCracken, GH; Mulholland, EK; Ogunlesi, O; Olsen, K; Qazi, S; Smith, A; Weber, AF; Weber, MW, 1999) |
| "Three opportunistic infections were observed early (first 6 months) after 2CdA therapy: pneumocystis pneumonia, retinitis due to toxoplasma in the patient who failed and legionella pneumonia in a patient retreated after relapse." | ( Bastie, JN; Castaigne, S; Cazals-Hatem, D; D'Agay, MF; Dabout, D; Daniel, MT; Degos, L; Dombret, H; Flandrin, G; Glaisner, S; Noel-Walter, MP; Poisson, D; Rabian, C, 1999) |
| "The treatment of intra-abdominal infections with I/C is shown to be more effective (97 deaths avoided/year) and less costly than with meropenem (with a saving of ITL 27,168 and 25,399 million/year for INHS and PIC, respectively)." | ( Attanasio, E; Basoli, A; Caprino, L; Carunchio, G; Russo, P, 2000) |
| "Treatment of established infection with vitamin A is effective in measles-associated complications, but is not as useful in the majority of diarrhoeal or respiratory syndromes." | ( Tomkins, A, 2000) |
| "Viral infections, including human immunodeficiency virus, hepatitis A, B and C viruses, and parvovirus have been seen in vWD and the efficacy of viral attenuation processes is a major criterion for the selection of treatment by physicians." | ( Cohen, AJ; Ewenstein, BM; Kessler, CM, 2001) |
| "The role of infection in the genesis of preeclampsia needs to be studied in depth because it may involve a fundamental change in the prevention and treatment of preeclampsia." | ( Casas, JP; López-Jaramillo, P; Serrano, N, 2001) |
| "The treatment of dental infection could occasionally mean avoiding immunosuppressive therapy in certain cases." | ( Besancenot, JF; Bielefeld, P; Duong, M; Friedel, J; Gresset, AC; Lévêque, L; Turcu, A, 2001) |
| "Many women with urinary tract infections receive inappropriate treatment because of difficulties differentiating upper and lower tract infection sites or failure to consider personal factors such as contraceptive method used." | ( , 1997) |
| "This paper looks at HIV infection and treatment behavior in India." | ( Kaur, P; Kaur, V; Singh, S, 1992) |
| "The optimal treatment for bleb-related infections is evolving, but consensus is that a high degree of vigilance and aggressive treatment are key to minimizing the potentially blinding nature of this complication." | ( Mac, I; Soltau, JB, 2003) |
| "Cytolytic therapy increases risk of infection, and should be avoided in pts." | ( Durmała, J; Foremny, J; Konecka-Mrówka, D; Kozłowska, K; Nozyński, J; Pisarska, H; Przybylski, R; Swierad, M; Szewczyk, M; Trzcińska, I; Wojarski, J; Zakliczyńska, H; Zakliczyński, M; Zembala, M, 2003) |
| "Despite leptomeningeal infection during prolonged treatment, epidural analgesia at the lumbar level provided analgesia using very large doses of local anesthetics combined with clonidine and morphine." | ( Eikermann, M; Exner, HJ; Peters, J, 2003) |
| "As an established infection-imaging modality, nuclear medicine plays a vital health-care role in the diagnosis and subsequent effective treatment of this condition." | ( Hughes, DK, 2003) |
| "Hand infections can result in significant morbidity if not appropriately diagnosed and treated." | ( Clark, DC, 2003) |
| "The treatment of biliary tract infections requires antibiotics and an appropriate surgical procedure." | ( Bonet, A; García-Oria, M; Rodríguez, I; Rodríguez, JI; Roig, J; Sirvent, JM, 2003) |
| "Prevention of these infections should be based on patients' education (compliance with diabetes treatment, hand care, prompt visit to the doctor) and General Practitioners' training for an adequate treatment and/or a rapId patient referral to hospital." | ( Amani, ME; Benkhelifa, T; Benotmane, A; Faraoun, K; Mohammedi, F, 2004) |
| "We examined catheter insertions, VA infections, and anemia management in Medicare, rHuEPO-treated, chronic hemodialysis patients." | ( Collins, AJ; Obrador, GT; Pereira, BJ; Roberts, TL; St Peter, WL, 2004) |
| "To assess the risk of serious infections following 22 weeks of infliximab therapy, and to further characterize the safety profile of infliximab in combination with background treatments during 1 year in patients with rheumatoid arthritis (RA) with various comorbidities." | ( Berman, A; Geusens, P; Han, J; Rahman, MU; Strusberg, I; Westhovens, R; Yocum, D, 2006) |
| "Information on infection-related exposures between birth and disease diagnosis was ascertained by administering a structured questionnaire to the mother and the index subject." | ( Amre, DK; Chotard, V; Costea, F; Grimard, G; Israel, D; Krupoves, A; Lambrette, P; Law, L; Mack, D; Seidman, EG, 2006) |
| "Children frequently suffer infections accompanied by fever, which is commonly treated with acetaminophen (paracetamol), a use not devoid of risk." | ( Derasse, M; Klein, P; Weiser, M, 2005) |
| "Severe infections related to treatment are common in patients with multiple myeloma (MM)." | ( Mølle, I; Peterslund, NA; Steffensen, R; Thiel, S, 2006) |
| "Myelosuppression and infections were dose limiting whereas posttreatment complications, including fatalities, resulted from infections." | ( Ballabeni, P; Cerny, T; Fey, M; Hess, U; Laurencet, F; Luthi, JM; Plancherel, C; Rufener, B; Zulian, GB, 2007) |
| "Patients with genetic susceptibility to infection may benefit from less potent immunosuppressive therapy and more intense preventive measures." | ( Arias, M; Fernández-Fresnedo, G; Gómez-Alamillo, C; González-Cotorruelo, J; Leyba-Cobián, F; López-Hoyos, M; Palomar, R; Piñera, C; Rodrigo, E; Ruiz, JC; Sánchez-Velasco, P, 2007) |
| "Severe abdominal infection results in increased apoptosis of the intestinal epithelial cells in rats, and L-Arg treatment may reduce the cell apoptosis." | ( Lei, ST; Liu, JF; Ren, YF; Wu, CT; Zhang, JH, 2007) |
| "Early diagnosis of musculoskeletal infections is the key to successful therapy and prevention of complications." | ( Strobel, K; Stumpe, KD, 2007) |
| "We assessed the frequency of infection at the time of MR contrast administration in a group of NSF patients." | ( Golding, LP; Provenzale, JM, 2008) |
| "The association of NSF with infection was highly significant, supporting the hypothesis that infection at the time of MR contrast administration in renal failure patients predisposes to NSF." | ( Golding, LP; Provenzale, JM, 2008) |
| "There were 73 infections in 73 subjects (23% of the treated population); 4/73 required hospitalization." | ( Antonini, MG; Babudieri, S; Baiguera, C; Carosi, G; Dettori, G; Fenu, L; Maida, I; Manno, D; Mura, MS; Puoti, M; Zanini, B, 2008) |
| "The risk of major infections in patients with SLE is mostly influenced by treatment." | ( Aguirre, C; Egurbide, MV; Martinez-Berriotxoa, A; Olivares, N; Ruiz-Arruza, I; Ruiz-Irastorza, G, 2009) |
| "Newborns with postnatal infections and hypotension requiring therapy were at higher risk of white matter injury (p < 0." | ( Bowen-Roberts, T; Brant, R; Chau, V; McFadden, DE; Miller, SP; Poskitt, KJ; Sargent, MA; Soulikias, W; Synnes, A, 2009) |
| "Judged by the mouse infections with the strains here used, penicillin X is the penicillin of choice in the treatment of infections with pneumococcus Type I and hemolytic streptococci." | ( Eagle, H, 1947) |
| "We identified 92 infections among these 70 patients; therapy for 54 (58." | ( Chun, ED; Collins, CD; Malani, PN; Rodgers, PE; Vitale, CA, 2010) |
| "Bacterial infections during treatment with peginterferon alfa and ribavirin are not associated with neutropenia." | ( de Knegt, RJ; Hansen, BE; Janssen, HL; Roomer, R, 2010) |
| "The individual risk of infection and requirements for medical treatment after high-dose chemotherapy have been unpredictable." | ( Ehninger, G; Einsele, H; Emmerich, B; Engert, A; Franke, D; Freund, M; Giagounidis, A; Grimminger, W; Heinisch, H; Hellmann, P; Hentrich, M; Hinke, A; Hübel, K; Metzner, B; Salwender, H; Sandherr, M; Scheid, C; Schlimok, G; Schwerdtfeger, R; Sezer, O; Silling, G; Straka, C; Wandt, H, 2011) |
| "Significantly more viral infections, protocol violations, and need for antilipid therapy occurred among patients receiving sirolimus, but we did not observe differences between the groups with regard to infections requiring hospitalization or new-onset diabetes." | ( Brown, R; Burke, GW; Chen, L; Ciancio, G; Gaynor, JJ; Guerra, G; Hanson, L; Kupin, W; Livingstone, AS; Roth, D; Ruiz, P; Sageshima, J; Tueros, L; Zarak, A, 2011) |
| "To explore the relationship of serious infection risk with current and prior oral glucocorticoid (GC) therapy in elderly patients with rheumatoid arthritis (RA)." | ( Abrahamowicz, M; Beauchamp, ME; Bernatsky, S; Dixon, WG; Ray, DW; Suissa, S; Sylvestre, MP, 2012) |
| "GC therapy is associated with infection risk in older patients with RA." | ( Abrahamowicz, M; Beauchamp, ME; Bernatsky, S; Dixon, WG; Ray, DW; Suissa, S; Sylvestre, MP, 2012) |
| "CsA-treated patients with recurrent infections had significantly lower RGE rates (27%) than children without recurrent infections (50%; p = 0." | ( Billing, H; Breil, T; Engelmann, G; Giese, T; Schmidt, J; Schmitt, C; Schmitt, CP; Tönshoff, B, 2012) |
| "Inclusion criteria were suspected infection evidenced by administration of antibiotics in the ED and measurement of whole blood lactate in the ED." | ( Jones, AE; Kline, JA; Puskarich, MA; Summers, RL, 2012) |
| "olivieri to treat infections with emphasis to isolate and characterize the active principle responsible for antibacterial, antifungal and cytotoxic activities and its exploitation as therapeutic agent." | ( Bokhari, J; Jan, S; Khan, MR; Rashid, U; Shah, NA, 2013) |
| "Many acute hand and upper extremity infections should be treated as surgical emergencies to avoid stiffness, contracture, pain, and amputation." | ( Abrams, RA; Franko, OI, 2013) |
| "The first rule to effectively treat the infection is always prevention, but when the infection has been established the only solution is given by an early diagnosis and proper medical care and often surgical treatment." | ( Jamar, FX; Müller-Hülsbeck, S; Setacci, C, 2014) |
| "In response to concerns about serious infections, in early 2006 Planned Parenthood changed the route of misoprostol administration to buccal and required either routine antibiotic coverage or universal screening and treatment for chlamydia; in July 2007, Planned Parenthood began requiring routine antibiotic coverage for all medical abortions." | ( Fjerstad, M; Lichtenberg, ES; Nucatola, D; Trussell, J, 2014) |
| "Musculoskeletal infections, particularly those in regions of complex anatomy and at postoperative sites, can be difficult to evaluate clinically, yet accurate diagnosis is essential to treat these infections promptly and correctly." | ( Cho, SY; Rowe, SP, 2014) |
| "The risks of CCVD, infection, and hospitalization were significantly higher among patients who were treated with high weekly doses of intravenous iron compared with no intravenous iron." | ( Fujimoto, S; Fukatsu, A; Hara, T; Hase, H; Inoue, T; Itakura, I; Joki, N; Kitamura, K; Kiyomoto, H; Kuragano, T; Matsuda, A; Matsumura, O; Murata, T; Nakanishi, T, 2014) |
| "A total of 76% of the treated infections were hospital-acquired." | ( Bedos, JP; Bret, P; Dupont, H; Montravers, P, 2014) |
| "The overall risk of infection (including serious infection) and mortality rates in RA patients treated with tofacitinib appear to be similar to those observed in RA patients treated with biologic agents." | ( Benda, B; Cohen, S; Gomez-Reino, JJ; Krishnaswami, S; Kwok, K; Nduaka, CI; Radominski, SC; Riese, R; Soma, K; Valdez, H; Wang, L; Wood, SP, 2014) |
| "A more judicious approach to infection management may reduce unnecessary treatment in these frail patients, who most often have comfort as their primary goal of care, and the public health threat of MDRO emergence." | ( D'Agata, E; Givens, JL; Habtemariam, D; Kiely, DK; Loeb, MB; Mitchell, SL; Shaffer, ML, 2014) |
| "Characterization of graft infections according to the graft location did show that these infections differ in terms of their characteristics and that the prognosis for treatment seems to be influenced by the location of the infection." | ( Battegay, M; Elzi, L; Erb, S; Gurke, L; Sidler, JA; Weisser, M; Widmer, AF, 2014) |
| "All documented episodes of infection that required treatment with antibiotics were regarded as infectious episodes." | ( Kang, RY; Kim, HS; Kim, KS; Lee, BK; Lee, JY; Lee, SH; Lee, YJ; Suh, SY; Yoo, KE, 2015) |
| "Early detection of infection is essential for initial management of cancer patients with chemotherapy-associated febrile neutropenia in the emergency department." | ( Albaladejo-Otón, MD; Cerezuela-Fuentes, P; Consuegra-Sánchez, L; de Béjar-Almira, Á; Español-Morales, I; Esteban-Torrella, P; García de Guadiana-Romualdo, L; Hernando-Holgado, A; Jiménez-Santos, E; Viqueira-González, M, 2015) |
| "We evaluated hospitalized infections among patients treated with biologic agents for RA who initiated denosumab or zoledronic acid (ZA), a parenteral bisphosphonate without known associations with infection." | ( Chen, L; Curtis, JR; Delzell, E; Saag, KG; Xie, F; Yun, H, 2015) |
| "Serious infections occurred in 13% of the patients treated with prednisolone versus 7% of those who did not receive prednisolone (P=0." | ( Allison, M; Austin, A; Bowers, M; Day, CP; Downs, N; Forrest, EH; Gleeson, D; Grant, A; Hood, S; MacGilchrist, A; Masson, S; McCune, A; Mellor, J; O'Grady, J; Patch, D; Ratcliffe, I; Richardson, P; Roderick, P; Ryder, S; Stanton, L; Thursz, MR; Vergis, N; Wright, M, 2015) |
| "The rate of severe infection with the use of IMiD-based therapy was 13." | ( Harrison, SJ; Slavin, MA; Teh, BW; Thursky, KA; Worth, LJ, 2016) |
| "Life-threatening infection as an adverse reaction to cytotoxic therapy of cancer remains a major problem, potentially limiting efficacy." | ( Allan, JM; Boddy, AV; Cresti, N; Griffin, MJ; Jamieson, D; Lee, J; Muro, S; Pouché, L; Sludden, J; Sunter, N; Verrill, MW, 2017) |
| "Risk factors for serious infections during maintenance treatment were evaluated using Poisson regression." | ( Cortazar, FB; Laliberte, K; Niles, JL; Owens, CT; Pendergraft, WF; Wenger, J, 2017) |
| "Serious infections during maintenance therapy occurred at a rate of 0." | ( Cortazar, FB; Laliberte, K; Niles, JL; Owens, CT; Pendergraft, WF; Wenger, J, 2017) |
| "We compared the effects of infection on clinical outcomes of patients treated with and without prednisolone, and identified risk factors for development of infection in SAH." | ( Allison, M; Atkinson, SR; Austin, A; Forrest, EH; Gleeson, D; Knapp, S; Masson, S; Maurice, J; McCune, A; Patch, D; Richardson, P; Ryder, SD; Thursz, MR; Vergis, N; Wright, M, 2017) |
| "Development of infection was associated with increased 90-day mortality in patients with SAH treated with prednisolone, independent of model for end-stage liver disease or Lille score (OR, 2." | ( Allison, M; Atkinson, SR; Austin, A; Forrest, EH; Gleeson, D; Knapp, S; Masson, S; Maurice, J; McCune, A; Patch, D; Richardson, P; Ryder, SD; Thursz, MR; Vergis, N; Wright, M, 2017) |
| "Here we summarize the available data on infections in MDS patients in general and particularly those treated with 5-azacitidine." | ( Hofmann, WK; Nolte, F; Platzbecker, U; Radsak, M; Schmidt, CS, 2017) |
| "17%; p = NS), but infection rates were lower among IVI-treated patients (18% vs." | ( Castellví, J; Gómez-Ramírez, S; Jericó, C; Laso-Morales, M; Muñoz, M; Pontes, C; Roig-Martínez, I; Viso, L, 2017) |
| "QOD CS treatment leads to a lower infection rate and less CS dependence than does daily treatment; both RA treatments are equally effective." | ( Kishimoto, M; Ohde, S; Okada, M; Suda, M; Tsuda, T, 2018) |
| "While opportunistic infections and viral reactivations occur with both ibrutinib and idelalisib, these complications are less common and less severe with ibrutinib, especially when used as monotherapy without additional immunosuppressive agents." | ( Pleyer, C; Sun, C; Wiestner, A, 2018) |
| "Serious infections were those associated with hospitalization, the use of intravenous antimicrobial therapy and/or those that led to death." | ( Ashcroft, DM; Evans, I; Griffiths, CEM; Lunt, M; McElhone, K; Murphy, R; Ormerod, AD; Reynolds, NJ; Smith, CH; Walton, S; Warren, RB; Yiu, ZZN, 2019) |
| "and the frequency of deep hand infection, the spread of infection to the surrounding tissues, increase in the number of complications, reoperations, and duration of treatment." | ( Kim, DY; Kokorin, VV; Kolodkin, BB; Krainyukov, PE; Pogosov, NY; Safonov, OV; Travin, NO, 2017) |
| "379 patients with hand infections treated in our clinic from 2007 to 2014 were evaluated retrospectively for time of presentation to hand surgeon, time of trauma, length of stay, and frequency of necessary operations." | ( Dastagir, K; Könneker, S; Kuhbier, JW; Luketina, R; Vogt, PM; Ziegler, A, 2019) |
| "However, the infection risk with different IS drug treatments has not been systematically compared." | ( Hu, B; Kuang, F; Liu, D; Qing, S; Yang, Y; Yu, X, 2019) |
| "To investigate signs of infection and infection-related complications of apical periodontitis (AP) in patients who underwent chemotherapy for lymphoma." | ( Hasséus, B; Johansson, JE; Jonasson, P; Skallsjö, K, 2020) |
| "Knowledge regarding infection-related complications of AP in patients with lymphoma treated with chemotherapy will guide clinical decision-making by identifying those patients who warrant treatment." | ( Hasséus, B; Johansson, JE; Jonasson, P; Skallsjö, K, 2020) |
| "To compare the risk of serious infections between the use of tumor necrosis factor inhibitors (TNFi) plus methotrexate (MTX) versus triple therapy among rheumatoid arthritis (RA) patients in a real-world setting." | ( Desai, RJ; Jin, Y; Kang, EH; Kim, SC; Tong, AY, 2020) |
| "Incidences of infections and serious treatment-emergent adverse events were similar across treatment groups." | ( Arnold, DL; Bar-Or, A; Cohen, JA; Comi, G; Cree, BAC; Hartung, HP; Huang, V; Kappos, L; Kubala Havrdová, E; Minton, N; Montalban, X; Raghupathi, K; Selmaj, KW; Sheffield, JK; Steinman, L, 2019) |
| "Even less is known about infection risk associated with rituximab, which is extensively used off-label to treat MS in Sweden." | ( Alping, P; Burman, J; Fink, K; Fogdell-Hahn, A; Frisell, T; Gunnarsson, M; Hillert, J; Langer-Gould, A; Luna, G; Lycke, J; Nilsson, P; Olsson, T; Piehl, F; Salzer, J; Svenningsson, A; Vrethem, M, 2020) |
| "To examine the risk of serious infections associated with disease-modifying treatments for MS." | ( Alping, P; Burman, J; Fink, K; Fogdell-Hahn, A; Frisell, T; Gunnarsson, M; Hillert, J; Langer-Gould, A; Luna, G; Lycke, J; Nilsson, P; Olsson, T; Piehl, F; Salzer, J; Svenningsson, A; Vrethem, M, 2020) |
| "The rate of infections was lowest with interferon beta and GA; among newer treatments, off-label use of rituximab was associated with the highest rate of serious infections." | ( Alping, P; Burman, J; Fink, K; Fogdell-Hahn, A; Frisell, T; Gunnarsson, M; Hillert, J; Langer-Gould, A; Luna, G; Lycke, J; Nilsson, P; Olsson, T; Piehl, F; Salzer, J; Svenningsson, A; Vrethem, M, 2020) |
| "Severe infections developed in 10 patients during emapalumab treatment." | ( Ahlmann, M; Allen, C; Ballabio, M; Cesaro, S; Dapena Diaz, JL; De Benedetti, F; de Min, C; Degar, B; Fagioli, F; Garrington, TP; Grom, A; Henry, M; Jacqmin, P; Jordan, MB; Lapeyre, G; Locatelli, F; Putti, MC; Rao, A; Rizzari, C; Sevilla, J, 2020) |
| "To evaluate the incidence of infection in patients with active rheumatoid arthritis (RA) treated with baricitinib, an oral selective Janus kinase (JAK)1 and JAK2 inhibitor." | ( Bradley, JD; Byers, NL; Dickson, CL; Dougados, M; Fleischmann, R; Genovese, MC; Harigai, M; Hyslop, DL; Issa, M; Lindsey, S; Nishikawa, A; Rooney, TP; Smolen, JS; Takeuchi, T; Winthrop, KL; Witt, S, 2020) |
| "Treatment-emergent infections were higher for baricitinib versus placebo (exposure-adjusted incidence rate (IR)/100 PY: placebo 75." | ( Bradley, JD; Byers, NL; Dickson, CL; Dougados, M; Fleischmann, R; Genovese, MC; Harigai, M; Hyslop, DL; Issa, M; Lindsey, S; Nishikawa, A; Rooney, TP; Smolen, JS; Takeuchi, T; Winthrop, KL; Witt, S, 2020) |
| "Increased rates of treatment-emergent infections including HZ were observed in patients with RA treated with baricitinib, consistent with baricitinib's immunomodulatory mode of action." | ( Bradley, JD; Byers, NL; Dickson, CL; Dougados, M; Fleischmann, R; Genovese, MC; Harigai, M; Hyslop, DL; Issa, M; Lindsey, S; Nishikawa, A; Rooney, TP; Smolen, JS; Takeuchi, T; Winthrop, KL; Witt, S, 2020) |
| "Causes included worsening infection in 18%, venous access problems in 11%, acute events unrelated to infection in 19%, treatment intolerance in 19%, progression of underlying comorbidity in 20%, and social and other problems in 13%." | ( Barnes, A; Nunez, M, 2021) |
| "To assess the relationship between infection risk and abatacept (ABA) exposure levels in patients with polyarticular-course juvenile idiopathic arthritis (pJIA) following treatment with subcutaneous (SC) and intravenous (IV) ABA." | ( Brunner, HI; Cimaz, R; Dare, J; Espada, G; Faugier, E; Ferrandiz, M; Gandhi, Y; Gerloni, V; Louw, I; Lovell, DJ; Martini, A; Nys, M; Passarell, J; Quartier, P; Ruperto, N; Silva, CA; Tzaribachev, N; Vega-Cornejo, G; Wagner-Weiner, L; Wong, R, 2021) |
| "Severe infections incidence was 23% during 17-month median follow-up; cumulative incidence was higher in the first 3-6 months of targeted drug treatment and then decreased." | ( Alonso, C; Ángel Hernández-Rivas, J; Bastidas, G; Bastos-Oreiro, M; Bocanegra, A; Carpio, C; Comai, A; Cordoba, R; De Nicolás, R; Del Campo, R; Fernández-Cruz, A; García-Suárez, J; Grande, C; Jiménez-Ubieto, A; López-Guillermo, A; López-Jiménez, J; Luis Plana, J; Marquet, J; Martín, X; Martínez-López, J; Mas-Ochoa, C; Morillo, D; Navarro-Matilla, B; Núñez, L; Prat, M; Romero, S; Ruiz-Camps, I; Seri, C; Serna, Á; Stefania Infante, M; Vásquez, L; Villafuerte, P, 2021) |
| "We asked if the occurrence of acute infections during chemotherapy for advanced-stage Hodgkin lymphoma (HL) decreased when COVID-19 protection measures were in effect." | ( Borchmann, P; Dierlamm, J; Engert, A; Fuchs, M; Gillessen, S; Haenel, M; Hallek, M; Huettmann, A; Jacob, AS; Kaul, H; Kreissl, S; Lehmann, C; Martin, S; Mathas, S; Meissner, J; Momotow, J; Pluetschow, A; Schaub, V; Zimmermann, A, 2022) |
| "We analyzed the occurrence of infections during all documented eBEACOPP cycles starting between 01 March and 30 June of 2017 to 2020 in patients treated within the GHSG HD21 study in Germany and compared the infection rates and characteristics by logistic regression models and means of descriptive statistics." | ( Borchmann, P; Dierlamm, J; Engert, A; Fuchs, M; Gillessen, S; Haenel, M; Hallek, M; Huettmann, A; Jacob, AS; Kaul, H; Kreissl, S; Lehmann, C; Martin, S; Mathas, S; Meissner, J; Momotow, J; Pluetschow, A; Schaub, V; Zimmermann, A, 2022) |
| "The significant decrease of infections during chemotherapy for HL during COVID-19 lockdown reveals the protective measures' potential to shield patients from transmissible pathogens." | ( Borchmann, P; Dierlamm, J; Engert, A; Fuchs, M; Gillessen, S; Haenel, M; Hallek, M; Huettmann, A; Jacob, AS; Kaul, H; Kreissl, S; Lehmann, C; Martin, S; Mathas, S; Meissner, J; Momotow, J; Pluetschow, A; Schaub, V; Zimmermann, A, 2022) |
| "Contemporary data on infections after intensive chemotherapy for acute myeloid leukemia (AML) are scarce." | ( Boeckh, M; Cheng, GS; Chung, EL; Delaney, C; Halpern, AB; Hill, JA; Huebner, EM; Kiem, ES; Kimball, LE; Leisenring, WM; Liu, C; Pergam, SA; Schonhoff, KG; Walter, RB; Walti, CS; Xie, H, 2023) |
| "Contemporary data on infections after intensive chemotherapy for acute myeloid leukemia (AML) are scarce." | ( Boeckh, M; Cheng, GS; Chung, EL; Delaney, C; Halpern, AB; Hill, JA; Huebner, EM; Kiem, ES; Kimball, LE; Leisenring, WM; Liu, C; Pergam, SA; Schonhoff, KG; Walter, RB; Walti, CS; Xie, H, 2023) |
| "Recently, serious infections related to the use of tofacitinib (TOF) for treatment of rheumatoid arthritis (RA) have raised considerable interest." | ( Brulhart, L; Ciurea, A; Dudler, J; Finckh, A; Gabay, C; Hasler, P; Kyburz, D; Möller, B; Mueller, RB; Riek, M; Scherer, A; Strahm, T; von Känel, S; von Kempis, J; von Mühlenen, I; Zufferey, P, 2023) |